Latest Product Development News

EML Payments Limited reported a 9% revenue increase and 13% rise in underlying EBITDA for FY25, while advancing its EML2.0 transformation and Project Arlo technology platform. Despite a net loss impacted by a shareholder class action provision, the company’s renewed client pipeline and strategic restructuring signal a pivotal phase ahead.

ReadyTech reported a solid 7.1% revenue increase in FY25, driven by $15.4 million in new enterprise contracts and a strategic push into AI-enhanced SaaS products. The company’s strong pipeline and AI initiatives set the stage for accelerated growth in FY26 and beyond.

Nine Entertainment reported a 2% revenue rise in FY25, powered by digital and subscription growth, while navigating EBITDA pressures and completing a major Domain stake sale.

SiteMinder Limited reported robust FY25 results with a 27.2% constant currency organic ARR increase and a return to positive underlying EBITDA, driven by its innovative Smart Platform and expanding global footprint.

MyEco Group reported a 9% increase in FY25 sales driven by an 82% jump in MyEco branded products, alongside a strategic operational restructure aimed at cutting costs and boosting supply chain flexibility.

Matrix Composites & Engineering Ltd posted a 12.1% revenue decline to $74.77 million for FY25, reporting a net loss of $2.2 million as subdued drilling buoyancy markets weighed on results despite strong growth in subsea buoyancy products.

Wagners Holding Company Limited reported a 120% increase in net profit after tax for FY25 despite a 10.4% revenue decline, driven by strong segment performance and cost management. The company also declared a higher fully franked final dividend of 3.2 cents per share.

Star Combo Pharma Limited reported a 7% increase in total revenue to $27.8 million for FY25, propelled by a 10% rise in its core OEM and Own Brands segment. The company’s profit before tax surged to $5.31 million, reflecting operational strength despite challenges in its Retail division.

Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.

Integrated Research reported steady pro-forma revenue in FY25 despite declines in statutory revenue and profits, driven by a softer renewals book and market uncertainty. The company’s product-led growth strategy gained momentum with new product launches and a major contract renewal.

Integrated Research Limited reported an 18% revenue decline and a 51% drop in net profit for FY25, while unveiling a strategic pivot towards AI-driven product innovation and cloud services.

Austco Healthcare has reported a robust FY25 with revenues climbing 40% to $81.4 million and EBITDA jumping 62% to $13 million, driven by organic growth and strategic acquisitions.